News
04-28-2011, 10:50 PM
MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.
More... (http://www.news-medical.net/news/20110429/MorphoSys-reaches-second-clinical-milestone-with-OncoMed-Pharmaceuticals.aspx)
More... (http://www.news-medical.net/news/20110429/MorphoSys-reaches-second-clinical-milestone-with-OncoMed-Pharmaceuticals.aspx)